Kidney cancer clinical trials

Explore recruiting kidney cancer clinical trials.

Recruiting kidney cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Kidney cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A PHASE II, MULTICENTRE, OPEN-LABEL STUDY OF CABOZANTINIB AS 2ND LINE TREATMENT IN SUBJECTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA WITH A CLEAR-CELL COMPONENT WHO PROGRESSED AFTER 1ST LINE TREATMENT WITH CHECKPOINT INHIBITORS

Germany, France

Therapeutic exploratory (Phase II) EU CTIS Study details

Kidney cancer

Sweden, France, Portugal, Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Efficacy of PErioperative PEmbrolizumab treatment in patients with resectable metastases from kidney cancer. The PE-PE study

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

EORTC-2361-GUCG: Phase II trial evaluating the efficacy of 177Lutetium-PSMA treatment in patients with metastatic clear cell Renal Carcinoma Cell with progressive disease on first-line or second-line systemic treatment (RENALUT)

Spain, France, Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2 BIOmarker driven trial with Nivolumab and Ipilimumab or VEGFR tKi in naïve metastatic Kidney cancer

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Digital monitoring of self-reported symptoms by patients treated with Cabozantinib plus Nivolumab for advanced clear-cell renal carcinoma: The CANIQOL multicentre study

France

Therapeutic use (Phase IV) EU CTIS Study details

Kidney cancer trials by city

Kidney cancer in Toronto Kidney cancer in Vancouver Kidney cancer in Montreal Kidney cancer in Calgary Kidney cancer in Edmonton Kidney cancer in Ottawa Kidney cancer in Winnipeg Kidney cancer in Quebec City Kidney cancer in Hamilton Kidney cancer in Kitchener Kidney cancer in London Kidney cancer in Halifax Kidney cancer in New York Kidney cancer in Los Angeles Kidney cancer in Chicago Kidney cancer in Houston

Other conditions

Breast cancer Prostate cancer Lung cancer Non-small cell lung cancer Colorectal cancer Pancreatic cancer Ovarian cancer Melanoma Leukemia Lymphoma Multiple myeloma Bladder cancer Liver cancer Glioblastoma Head and neck cancer Cervical cancer Endometrial cancer Gastric cancer Age-related macular degeneration Diabetic retinopathy Glaucoma Dry eye disease HIV Hepatitis B